SGLT2 inhibitors have shown great promise in the management of diabetes mellitus and the prevention of cardiovascular complications, but increasing evidence suggests that their use can be associated with an increased risk of acute kidney injury. Insights into the mechanisms involved might help to identify individuals who are at risk of renal injury.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Skrtic, M. et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 57, 2599–2602 (2014).
Zinman, B., Lachin, J. M. & Inzucchi, S. E. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2016).
Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323–334 (2016).
Hahn, K., Kanbay, M., Lanaspa, M. A., Johnson, R. J. & Ejaz, A. A. Serum uric acid and acute kidney injury: a mini review. J. Advanced Research (in press).
Bjornstad, P. et al. Fructose and uric acid in diabetic nephropathy. Diabetologia 58, 1993–2002 (2015).
Kitamura, H. et al. Inhibition of myo-inositol transport causes acute renal failure with selective medullary injury in the rat. Kidney Int. 53, 146–153 (1998).
This work is supported by NIH grants DK109408-01A1 (to R.J.J.) and DK108859-01 (to M.A.L.)
R.J.J. and M.A.L. have patents and patent applications related to blocking fructose metabolism, and are members of Colorado Research Partners, which is a startup company that is attempting to make inhibitors of fructose metabolism. R.J.J. is also on the Scientific Board of XORT Therapeutics and Amway. The other authors declare no competing interests.
About this article
Cite this article
Hahn, K., Ejaz, A., Kanbay, M. et al. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol 12, 711–712 (2016). https://doi.org/10.1038/nrneph.2016.159
Nature Reviews Endocrinology (2021)
Clinical Journal of the American Society of Nephrology (2021)
Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
Expert Opinion on Drug Safety (2020)
SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?
Journal of Nephrology (2020)
No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro
International Journal of Molecular Sciences (2020)